These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 14871286

  • 1. Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease.
    Wong WM, Lai KC, Hui WM, Lam KF, Huang JQ, Hu WH, Wong NY, Lam CL, Xia HH, Chan AO, Lam SK, Wong BC.
    Aliment Pharmacol Ther; 2004 Feb 15; 19(4):455-62. PubMed ID: 14871286
    [Abstract] [Full Text] [Related]

  • 2. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K, Lind T, Wilder-Smith C.
    Eur J Clin Pharmacol; 2004 Oct 15; 60(8):531-9. PubMed ID: 15349707
    [Abstract] [Full Text] [Related]

  • 3. Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison.
    Frazzoni M, De Micheli E, Grisendi A, Savarino V.
    Aliment Pharmacol Ther; 2002 Jan 15; 16(1):35-9. PubMed ID: 11856076
    [Abstract] [Full Text] [Related]

  • 4. Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.
    Newton M, Burnham WR, Kamm MA.
    Eur J Gastroenterol Hepatol; 1998 Sep 15; 10(9):753-8. PubMed ID: 9831269
    [Abstract] [Full Text] [Related]

  • 5. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
    Bautista J, Fullerton H, Briseno M, Cui H, Fass R.
    Aliment Pharmacol Ther; 2004 May 15; 19(10):1123-30. PubMed ID: 15142202
    [Abstract] [Full Text] [Related]

  • 6. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.
    Katz PO, Hatlebakk JG, Castell DO.
    Aliment Pharmacol Ther; 2000 Jun 15; 14(6):709-14. PubMed ID: 10848653
    [Abstract] [Full Text] [Related]

  • 7. Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole.
    Frazzoni M, De Micheli E, Grisendi A, Savarino V.
    Aliment Pharmacol Ther; 2003 Jan 15; 17(2):235-41. PubMed ID: 12534408
    [Abstract] [Full Text] [Related]

  • 8. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood.
    Franco MT, Salvia G, Terrin G, Spadaro R, De Rosa I, Iula VD, Cucchiara S.
    Dig Liver Dis; 2000 Nov 15; 32(8):660-6. PubMed ID: 11142573
    [Abstract] [Full Text] [Related]

  • 9. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease.
    Johnson DA, Stacy T, Ryan M, Wootton T, Willis J, Hornbuckle K, Brooks W, Doviak M.
    Aliment Pharmacol Ther; 2005 Jul 15; 22(2):129-34. PubMed ID: 16011671
    [Abstract] [Full Text] [Related]

  • 10. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole.
    Mee AS, Rowley JL.
    Aliment Pharmacol Ther; 1996 Oct 15; 10(5):757-63. PubMed ID: 8899084
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
    Castell D, Bagin R, Goldlust B, Major J, Hepburn B.
    Aliment Pharmacol Ther; 2005 Jun 15; 21(12):1467-74. PubMed ID: 15948814
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
    Janczewska I, Sagar M, Sjöstedt S, Hammarlund B, Iwarzon M, Seensalu R.
    Scand J Gastroenterol; 1998 Dec 15; 33(12):1239-43. PubMed ID: 9930385
    [Abstract] [Full Text] [Related]

  • 13. Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison.
    Frazzoni M, Grisendi A, Lanzani A, Melotti G, De Micheli E.
    Dig Liver Dis; 2002 Feb 15; 34(2):99-104. PubMed ID: 11926567
    [Abstract] [Full Text] [Related]

  • 14. Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg.
    Bigard MA, Genestin E.
    Aliment Pharmacol Ther; 2005 Oct 01; 22(7):635-43. PubMed ID: 16181303
    [Abstract] [Full Text] [Related]

  • 15. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
    Frazzoni M, Manno M, De Micheli E, Savarino V.
    Dig Liver Dis; 2006 Feb 01; 38(2):85-90. PubMed ID: 16289976
    [Abstract] [Full Text] [Related]

  • 16. Dose-response relationship of lansoprazole to gastric acid antisecretory effects.
    Blum RA, Hunt RH, Kidd SL, Shi H, Jennings DE, Greski-Rose PA.
    Aliment Pharmacol Ther; 1998 Apr 01; 12(4):321-7. PubMed ID: 9690720
    [Abstract] [Full Text] [Related]

  • 17. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A, Celikel CA, Ozdogan O, Tözün N, Ulusoy NB, Kalayci C.
    J Gastroenterol Hepatol; 2005 Dec 01; 20(12):1886-91. PubMed ID: 16336449
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.